Recombinant Human ACE2 (HEK Expressed)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus that belongs to the Coronaviridae family1. Angiotensin I converting enzyme 2 (ACE2) is an exopeptidase that catalyses the conversion of angiotensin I to the nonapeptide angiotensin[1-9].2 , or the conversion of angiotensin II to angiotensin 1-7.3 ACE 2 has direct effects on cardiac function3, and is expressed predominantly in vascular endothelial cells of the heart and the kidneys.4 ACE2 plays a regulatory role in lung pathophysiology, including pulmonary fibrosis and acute lung disease. Activation of ACE2 by a small molecule can be a therapeutically relevant approach for treating and controlling Pulmonary Hypertension (PH).5 ACE2 may also have clinical potential as a novel molecular target for the treatment of pancreatic ductal adenocarcinoma (PDAC).6

This recombinant protein is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of proteins, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

This recombinant protein may be stored as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.